SuperGen, Inc., a pharmaceutical company, engages in the discovery, acquisition, development, and commercialization of therapies to treat patients with cancer. It offers Dacogen, a pyrimidine analog that decreases the amount of methylation at certain DNA sites. The company also involves in developing various therapeutic anticancer products focused on inhibitors of aurora-A, tyrosine kinase, and DNA methyltransferase. Its generic anti cancer products include Mitomycin and Paclitaxel for solid tumors. The company's formulation products include Mitozytrex; Partaject busulfan for neoplastic meningitis/bone marrow transplant in Phase I/II; Partaject Orathecin and Cremophor-free paclitaxel for solid tumors in pre clinical stage; and CZ 112 for solid tumors in Phase I. SuperGen's other product candidates include Avicine, a therapeutic vaccine in Phase II; and VEGF, an anti angiogenesis in pre clinical stage. It has collaborations with MGI PHARMA, Inc.; The Stehlin Foundation for Cancer Research; Warner-Lambert Company; Peregrine Pharmaceuticals; AVI BioPharma, Inc.; and University of Arizona. The company sells its products to clinics, hospitals, and hospital buying groups in the United States, as well as to drug distributors and wholesalers in the United States and Europe. SuperGen was founded in 1991 and is headquartered in Dublin, California.